Dual Targeted Therapy with P53 SiRNA and Epigallocatechingallate in a Triple Negative Breast Cancer Cell Model

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Apr 8

PMID 25849487

Citations 22

Authors

Cornelia Braicu

Valentina Pileczki

Laura Pop

Roxana Cojocneanu Petric

Sergiu Chira

Eve Pointiere

Patriciu Achimas-Cadariu

Ioana Berindan-Neagoe

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is a highly aggressive phenotype that is resistant to standard therapy. Thus, the development of alternative therapeutic strategies for TNBC is essential. The purpose of our in vitro study was to evaluate the impact of p53 gene silencing in conjunction with the administration of a natural compound, epigallocatechingallate (EGCG). RT2Profiler PCR Array technology was used to evaluate the impact of dual treatment on the main genes involved in apoptosis in the Hs578T cell culture model of TNBC. Gene expression analysis revealed 28 genes were significantly altered (16 upregulated and 12 downregulated) in response to combined p53 siRNA and EGCG treatment. Further analysis revealed that p53 siRNA and EGCG dual therapy leads to the activation of pro-apoptotic genes and the inhibition of pro-survival genes, autophagy, and cell network formation. These results indicate that this dual therapy targets both the apoptotic and angiogenic pathways, which may improve treatment effectiveness for tumors resistant to conventional treatment.

Citing Articles

Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer.

Sai B, Dinakar Y, Kumar H, Jain R, Kesharwani S, Kesharwani S Ther Deliv. 2024; 15(11):871-891.

PMID: 39320858 PMC: 11498026. DOI: 10.1080/20415990.2024.2400044.

Harnessing the nutriceutics in early-stage breast cancer: mechanisms, combinational therapy, and drug delivery.

Pradeep Prabhu P, Mohanty B, Lobo C, Balusamy S, Shetty A, Perumalsamy H J Nanobiotechnology. 2024; 22(1):574.

PMID: 39294665 PMC: 11411841. DOI: 10.1186/s12951-024-02815-8.

Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy.

Subhan M, Torchilin V Bioengineering (Basel). 2024; 11(8).

PMID: 39199788 PMC: 11351222. DOI: 10.3390/bioengineering11080830.

Epigallocatechin-3-gallate and cancer: focus on the role of microRNAs.

Wang C, Bai M, Sun Z, Yao N, Zhang A, Guo S Cancer Cell Int. 2023; 23(1):241.

PMID: 37838685 PMC: 10576883. DOI: 10.1186/s12935-023-03081-8.

The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment.

Marin V, Burgos V, Perez R, Maria D, Pardi P, Paz C Int J Mol Sci. 2023; 24(13).

PMID: 37445915 PMC: 10341956. DOI: 10.3390/ijms241310737.

References

Storvold G, Andersen T, Perou C, Frengen E . siRNA: a potential tool for future breast cancer therapy?. Crit Rev Oncog. 2006; 12(1-2):127-50. DOI: 10.1615/critrevoncog.v12.i1-2.70. View

Liu K, Lou J, Wen T, Yin J, Xu B, Ding W . Depending on the stage of hepatosteatosis, p53 causes apoptosis primarily through either DRAM-induced autophagy or BAX. Liver Int. 2013; 33(10):1566-74. PMC: 4283711. DOI: 10.1111/liv.12238. View

Chiorean R, Braicu C, Berindan-Neagoe I . Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?. Breast. 2013; 22(6):1026-33. DOI: 10.1016/j.breast.2013.08.007. View

Braicu C, Gherman C, Irimie A, Berindan-Neagoe I . Epigallocatechin-3-Gallate (EGCG) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells. J Nanosci Nanotechnol. 2013; 13(1):632-7. DOI: 10.1166/jnn.2013.6882. View

Walerych D, Napoli M, Collavin L, Del Sal G . The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis. 2012; 33(11):2007-17. PMC: 3483014. DOI: 10.1093/carcin/bgs232. View

Teodoro J, Evans S, Green M . Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med (Berl). 2007; 85(11):1175-86. DOI: 10.1007/s00109-007-0221-2. View

Kanwar J, Taskeen M, Mohammad I, Huo C, Chan T, Dou Q . Recent advances on tea polyphenols. Front Biosci (Elite Ed). 2011; 4(1):111-31. PMC: 3303150. DOI: 10.2741/363. View

Johnson R, Sabnis N, McConathy W, Lacko A . The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer. Pharmaceutics. 2013; 5(2):353-70. PMC: 3826456. DOI: 10.3390/pharmaceutics5020353. View

Chen W, Hsu K, Hung C, Lin Y, Yang N, Ho C . The anti-tumor efficiency of pterostilbene is promoted with a combined treatment of Fas signaling or autophagy inhibitors in triple negative breast cancer cells. Food Funct. 2014; 5(8):1856-65. DOI: 10.1039/c4fo00145a. View

10.

Freed-Pastor W, Prives C . Mutant p53: one name, many proteins. Genes Dev. 2012; 26(12):1268-86. PMC: 3387655. DOI: 10.1101/gad.190678.112. View

11.

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh J, Comber H . Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6):1374-403. DOI: 10.1016/j.ejca.2012.12.027. View

12.

Berindan-Neagoe I, Braicu C, Irimie A . Combining the chemotherapeutic effects of epigallocatechin 3-gallate with siRNA-mediated p53 knock-down results in synergic pro-apoptotic effects. Int J Nanomedicine. 2012; 7:6035-47. PMC: 3525046. DOI: 10.2147/IJN.S36523. View

13.

Chittaranjan S, Bortnik S, Dragowska W, Xu J, Abeysundara N, Leung A . Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer. Clin Cancer Res. 2014; 20(12):3159-73. DOI: 10.1158/1078-0432.CCR-13-2060. View

14.

Suzuki Y, Miyoshi N, Isemura M . Health-promoting effects of green tea. Proc Jpn Acad Ser B Phys Biol Sci. 2012; 88(3):88-101. PMC: 3365247. DOI: 10.2183/pjab.88.88. View

15.

Liu K, Shi Y, Guo X, Ouyang Y, Wang S, Liu D . Phosphorylated AKT inhibits the apoptosis induced by DRAM-mediated mitophagy in hepatocellular carcinoma by preventing the translocation of DRAM to mitochondria. Cell Death Dis. 2014; 5:e1078. PMC: 3944266. DOI: 10.1038/cddis.2014.51. View

16.

Pal S, Childs B, Pegram M . Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2010; 125(3):627-36. PMC: 3244802. DOI: 10.1007/s10549-010-1293-1. View

17.

Dai F, Chen Y, Song Y, Huang L, Zhai D, Dong Y . A natural small molecule harmine inhibits angiogenesis and suppresses tumour growth through activation of p53 in endothelial cells. PLoS One. 2013; 7(12):e52162. PMC: 3531399. DOI: 10.1371/journal.pone.0052162. View

18.

Braicu C, Gherman C . Epigallocatechin gallate induce cell death and apoptosis in triple negative breast cancer cells Hs578T. J Drug Target. 2012; 21(3):250-256. DOI: 10.3109/1061186X.2012.740673. View

19.

Tachibana H . Green tea polyphenol sensing. Proc Jpn Acad Ser B Phys Biol Sci. 2011; 87(3):66-80. PMC: 3066547. DOI: 10.2183/pjab.87.66. View

20.

White E . The role for autophagy in cancer. J Clin Invest. 2015; 125(1):42-6. PMC: 4382247. DOI: 10.1172/JCI73941. View